홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Ethyl Acetate → 2,2,2-trichloroethyl 3-[3-carbamoyl-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazolin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate

HRID 45800
노트
인쇄 미리보기

반응식

HRID 45800 반응식
[CH3:1][S:2][C:3]1[N:12]=[CH:11][C:10]2[CH:9]=[CH:8][C:7]3[C:13]([C:16]([NH2:18])=[O:17])=[N:14][NH:15][C:6]=3[C:5]=2[N:4]=1.CS(O[CH:24]1[CH2:30][CH:29]2[N:31]([C:32]([O:34][CH2:35][C:36]([Cl:39])([Cl:38])[Cl:37])=[O:33])[CH:26]([CH2:27][CH2:28]2)[CH2:25]1)(=O)=O.C(=O)([O-])[O-].[Cs+].[Cs+].C(OCC)(=O)C>CN(C=O)C.O>[C:16]([C:13]1[C:7]2[CH:8]=[CH:9][C:10]3[CH:11]=[N:12][C:3]([S:2][CH3:1])=[N:4][C:5]=3[C:6]=2[N:15]([CH:24]2[CH2:30][CH:29]3[N:31]([C:32]([O:34][CH2:35][C:36]([Cl:38])([Cl:39])[Cl:37])=[O:33])[CH:26]([CH2:27][CH2:28]3)[CH2:25]2)[N:14]=1)(=[O:17])[NH2:18]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

7

반응물 4

HCID 8857Ethyl AcetateHCID 10796Cesium carbonateHCID 86668393HCID 86668393, 화합물HCID 178503380HCID 178503380, 화합물

생성물 1

HCID 679754422,2,2-trichloroethyl 3-[3-carbamoyl-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazolin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate수율 70%

시약·촉매·용매 2

HCID 962
Water
용매
HCID 6228Dimethylformamide용매

실험 절차

8-(Methylsulfanyl)-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide 50 mg (0.193 mmol) in DMF (8 ml), were reacted with 2,2,2-trichloroethyl 3-[(methylsulfonyl)oxy]-8-azabicyclo[3.2.1]octane-8-carboxylate 200 mg (0.52 mmol) and cesium carbonate 140 mg (0.43 mmol) at 90° C. for 4 hours. The mixture was cooled at r.t. and portioned between ethyl acetate and water. The organic phase was washed with brine, dried over Na2SO4 and evaporated. The crude was purified by column chromatography eluting with DCM/EtOH 9/1 to provide 2,2,2-trichloroethyl 3-[3-carbamoyl-8-(methylsulfanyl)-1H-pyrazolo[4,3-h]quinazolin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate as a off-white solid 73 mg (70%). The compound (134 mmol) was dissolved in THF (5 ml), acetic acid (5 ml) and zinc dust 35 mg (0.536 mmol) were added. The mixture was heated up to 50° C. and stirred 18 hours. The volatiles were removed in vacuum and the residue was purified by chromatography eluting with DCM/MeOH 95/5. A further purification was required and was performed by prep-HPLC method 1, to obtain the title compound 25 mg (50%). LC/MS (254 nm) HPLC method 2 Rt 4.08 min. 1H NMR (401 MHz, DMSO-d6) δ 9.50 (s, 1H), 8.25 (d, J=8.67 Hz, 1H), 7.62-7.79 (m, 3H), 7.52-7.60 (m, 1H), 6.21-6.54 (m, OH), 3.68 (br. s., 2H), 2.76 (s, 2H), 2.22-2.36 (m, 2H), 2.02 (br. s., 2H), 1.78-1.98 (m, 5H). HRMS (ESI) calcd for C18H20N6OS [M+H]+ 369.1492 found 369.15.

후처리

  1. washThe organic phase was washed with brine
  2. dry with materialdried over Na2SO4
  3. customevaporated
  4. customThe crude was purified by column chromatography
  5. washeluting with DCM/EtOH 9/1

출처 및 근거

ORD 기록
ord-2f92b727fdff4b139f7522c0091c8188
출처 데이터셋
uspto-grants-2013_09
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US08541576B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트